Treatment regimen, treatment duration, and incidence of anti-r-hirudin antibodies during first course of hirudin (lepirudin) treatment
| Treatment regimen . | Patients (n) . | Treatment duration median (range) (days) . | Antihirudin-antibody– positive patients/total evaluable patients n (%) . |
|---|---|---|---|
| A1—HIT patients with thrombosis; 0.4 mg/kg bolus then 0.15 mg/kg × h adjusted by aPTT | 116 | 11 (0-104)* | 55/115 (47.8) |
| A2—HIT patients with thrombosis receiving thrombolysis; 0.2 mg/kg bolus then 0.1 mg/kg × h adjusted by aPTT | 9 | 10 (1-57)* | 3/9 (33.3) |
| B—HIT patients without thrombosis; 0.1 mg/kg × h | 61 | 8 (1-67)* | 23/60 (38.3) |
| C—During surgery using cardiopulmonary bypass; 0.25 mg/kg bolus then 5 mg boluses when r-hirudin concentration was below 2.5 μg/mL, followed by regimen B | 12 | 5 (1-25) | 3/12 (25) |
| Total | 198 | 10 (0-104) | 84†/196 (42.9) |
| Treatment regimen . | Patients (n) . | Treatment duration median (range) (days) . | Antihirudin-antibody– positive patients/total evaluable patients n (%) . |
|---|---|---|---|
| A1—HIT patients with thrombosis; 0.4 mg/kg bolus then 0.15 mg/kg × h adjusted by aPTT | 116 | 11 (0-104)* | 55/115 (47.8) |
| A2—HIT patients with thrombosis receiving thrombolysis; 0.2 mg/kg bolus then 0.1 mg/kg × h adjusted by aPTT | 9 | 10 (1-57)* | 3/9 (33.3) |
| B—HIT patients without thrombosis; 0.1 mg/kg × h | 61 | 8 (1-67)* | 23/60 (38.3) |
| C—During surgery using cardiopulmonary bypass; 0.25 mg/kg bolus then 5 mg boluses when r-hirudin concentration was below 2.5 μg/mL, followed by regimen B | 12 | 5 (1-25) | 3/12 (25) |
| Total | 198 | 10 (0-104) | 84†/196 (42.9) |